SynthesisObesity surgery2021
Metabolic Effects of Endoscopic Duodenal Mucosal Resurfacing: a Systematic Review and Meta-analysis.
Synthesis in Obesity surgery, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed.
- Endoscopic small bowel therapies for type 2 diabetes.Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition · 2026Review
- Endoscopy for Metabolic Diseases.Journal of clinical medicine · 2026Review
- 450-nm Blue Laser-Induced Gastric Mucosal Ablation Promotes Short-Term Weight Loss and Metabolic Benefits in Rats with Obesity.Obesity surgery · 2026Article
- Gastric Bipartition with Functional Duodenum Exclusion (GBp-FDE) as a Possible Surgical Conversion of Sleeve Gastrectomy in Patients with De Novo GERD and Obesity Recidivism: Preliminary Results of a Case Series.The American journal of case reports · 2025Article
- Microbiome and gut-liver interactions: From mechanisms to therapies.World journal of gastroenterology · 2025Review
- Duodenal mucosal ablation with irreversible electroporation in non-alcoholic fatty liver disease: Roadmap of the future treatment.World journal of gastroenterology · 2025Article
- Duodenal mucosal ablation by irreversible electroporation: Modulating the gut-liver axis in metabolic steatotic liver disease.World journal of hepatology · 2025Article
- Recent advances in bariatric endoscopy for obesity management: expanding the therapeutic spectrum.Singapore medical journal · 2025Article
- Duodenal mucosal ablation: An emerging therapeutic concept for metabolic dysfunction-associated fatty liver disease.World journal of gastroenterology · 2025Article
- Duodenal mucosal ablation with irreversible electroporation reduces liver lipids in rats with non-alcoholic fatty liver disease.World journal of gastroenterology · 2025Article
- Role of duodenal mucosal resurfacing in controlling diabetes in rats.World journal of diabetes · 2025Article
- Advances in Metabolic Bariatric Surgeries and Endoscopic Therapies: A Comprehensive Narrative Review of Diabetes Remission Outcomes.Medicina (Kaunas, Lithuania) · 2025Review
- Gut‑liver axis in liver disease: From basic science to clinical treatment (Review).Molecular medicine reports · 2025Review
- First clinical application of a novel duodenal mucosal ablation device for type 2 diabetes using radiofrequency vapor ablation.Endoscopy · 2024Article
- The evolution and current state of bariatric endoscopy in Western countries.Clinical endoscopy · 2024Review
- Highly functional duodenal stent with photosensitizers enables photodynamic therapy for metabolic syndrome treatment: Feasibility and safety study in a porcine model.APL bioengineering · 2024Article
- Role of endoscopic duodenojejunal bypass liner in obesity management and glycemic control.Clinical endoscopy · 2024Review
- Effects of dietary fibre on metabolic health and obesity.Nature reviews. Gastroenterology & hepatology · 2024Review
- Endoscopic Bariatric Therapy for Obesity and Metabolic Syndrome.The Korean journal of helicobacter and upper gastrointestinal research · 2023Review
- Clinical Classification of Obesity and Implications for Metabolic Dysfunction-Associated Fatty Liver Disease and Treatment.Diabetes, metabolic syndrome and obesity : targets and therapy · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Duodenal mucosal resurfacing (DMR) is an innovative endoscopic bariatric and metabolic therapy (EBMT) emerging in recent years. It uses the duodenum to achieve better glycemic and weight control. This study aimed to evaluate in a critical and systematic way the metabolic effects of this procedure. Electronic searches were performed evaluating the DMR procedure based on predefined inclusion and exclusion criteria. Changes in measured outcomes were evaluated using random-effects models by computing weighted mean differences (MD) and corresponding 95% CIs between pre-and post-procedure metabolic characteristics. Four studies were selected for qualitative and quantitative analysis. DMR demonstrated beneficial glycemic and hepatic metabolic effects among patients with non-insulin dependent type 2 diabetes (T2D) at 3 and 6 months post-procedure.
Indexed as
Identifiers
33417100What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.